A therosclerosis is the underlying cause of cardiovascular disease (CVD), which is the leading cause of mortality worldwide. 1 CVD is initiated by the accumulation of lipids, necrotic cells, and fibrous elements in the neointima of medium and large arteries. 2, 3 The primary cells that contribute to atherosclerotic lesion formation are endothelial cells, vascular smooth muscle cells, and macrophages. 4-6 Plaque formation results from the infiltration of circulating monocytes in the subendothelial space, where they differentiate into macrophages and subsequently internalize modified lipoproteins and further differentiate into foam cells. 7 Therefore, further clarification of the mechanisms leading to macrophage accumulation is important to prevent plaque rupture and subsequent life-threatening clinical complications, such as myocardial infarction and stroke.
reported direct evidence that NFIA was involved in atherosclerosis until now.
Non-protein-coding RNAs (ncRNAs) have gained the attention of researchers in many fields and, consequently, the number of published articles continues to grow exponentially. 14 Conventionally, ncRNAs are divided into 2 main categories: short ncRNAs (<200 bp) and long ncRNAs (lncRNAs; >200 bp). 15 The discovery of numerous human lncRNA transcripts has dramatically altered our understanding of cell biology, especially in the field of oncology. 16, 17 However, there has been limited research focused on the effects of lncRNA on CVD until now. 18 A large prospective study by Zhang et al 19 found that transcript expression of a specific lncRNA antisense noncoding RNA in the INK4 locus was correlated with the incidence of stroke risk and recurrence. The natriuretic peptide precursor A (NPPA) gene product is usually expressed in only fetal atrial and ventricular myocardium but was also found to be reactivated in the ventricular myocardium of patients exhibiting hypertrophy and heart failure and is, therefore, considered a biomarker of heart disease. 20 NPPA-antisense lncRNA has been shown to modulate alternative splicing of the NPPA gene and thus has potential involvement in CVD. 21 In addition, lncRNAs, including Braveheart (AK143260), cardiac troponin I-antisense, β-myosin heavy chain-antisense, atrial myosin alkali light chain 1-antisense, the 3′ untranslated region of myotonin-protein kinase, and myocardial infarction-associated transcript, are critical to cardiac development and disease. 22 Therefore, the effects and mechanisms of lncRNA in CVD, especially atherosclerosis, has become an important area of research.
In the present study, microarray analysis revealed that lncRNA RP5-833A20.1 expression was upregulated, whereas NFIA expression was downregulated in human acute monocytic leukemia (THP-1) macrophage-derived foam cells.
Furthermore, RP5-833A20.1 reduced cholesterol efflux from THP-1 macrophage-derived foam cells, which was associated with increased miR-382-5p expression and inhibited NFIA expression. In addition, we showed that atherosclerosis development was influenced by NFIA via expression regulation of genes and proteins involved in the maintenance of cholesterol homeostasis and inflammatory reactions.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Oxidized Low-Density Lipoprotein/Acetylated Low-Density Lipoprotein Upregulated LncRNA RP5-833A20.1 Expression and Downregulated NFIA Expression
Plaque formation is dependent on infiltration of circulating monocytes to the subendothelial space, where they differentiate into macrophages and subsequently internalize modified lipoproteins and further differentiate into foam cells. 7 To investigate possible changes in RNA expression during macrophage formation, we performed microarray analysis of THP-1 macrophages and THP-1 macrophage-derived foam cells using the Arraystar probe data set, which included 24 748 lncRNAs and 24 420 coding transcripts ( Figure 1A ). lncRNA and mRNA expression profiles from THP-1 macrophages (3 samples) and THP-1 macrophage-derived foam cells (3 samples) were produced using the Arraystar Human LncRNA Array v2.0 platform (www.arraystar.com). There were 100 differentially expressed lncRNAs and 63 mRNAs (fold change >3; P value <0.01). The 63 differentially expressed mRNA transcripts correlated with all 24 748 lncRNAs and a peak value <−0.5 was obtained ( Figure 1C ), indicating that most lncRNAs could inhibit mRNA expression. Further selection of lncRNAs and mRNAs used in the analysis was performed by looking up the genomic locations of these molecules. We added more lncRNAs near to the selected 63 coding genes (distance, <300 kb) and more mRNAs near to the selected 100 lncRNA (distance, <300 kb). Analysis of enriched biological data revealed 157 relevant lncRNAs and 98 mRNAs (Figure IB and Tables  I and II in the online-only Data Supplement). We selected 157 lncRNAs and 98 mRNAs that showed strong correlations to one another (+1, positive correlation; −1, negative correlation), indicating the presence of enriched signaling between the biological genes and lncRNAs ( Figure 1D ). Hierarchical clustering based on a selected set of 98 mRNAs and 157 lncRNAs revealed that most of the set were upregulated in the treatment group, suggesting a concerted mRNA and lncRNA upregulation in the treatment group ( Figure 1E ). Moreover, we performed Pearson correlation and selected additional 40 mRNA transcripts near to the differentially expressed 157 lncRNAs (Pearson correlation, >0.9 or <−0.9; distance, <100 kb). Gene networks were constructed using GeneGo Metacore data mining software and Ingenuity Pathway Analysis software with the 98 selected genes as indicated above and the additional 40 genes, suggesting that several important pathways were significantly regulated. Network analysis was first performed to identify genes that played pivotal roles in foam cell formation ( Figure 1F ). High-scoring gene networks (P<0.05; score >3) are further illustrated by Figure IA to IE in the online-only Data Supplement and were associated with signaling in atherosclerosis, colorectal cancer metastasis, G-protein-coupled receptors, oncogenic factors, and osteoclast and chondrocyte function in rheumatoid arthritis. Next, we investigated the localization of the aforementioned 157 lncRNAs and 98 mRNAs through the University of California Santa Cruz Genome Browser (http://genome.ucsc.edu) and found that lncRNA RP5-833A20.1 was located in intron 2 of the NFIA gene and had an opposite transcription direction to that of NFIA ( Figure 1G ). Recent studies indicate that lncRNA function can be inferred from its location and will probably affect expression of nearby protein-coding genes. [23] [24] [25] [26] In addition, the lncRNA product may modulate neighboring gene expression in cis, 26, 27 affect distantly located genes in trans. 28, 29 Several previous studies indicate that opposite transcription of lncRNA might inhibit the expression of neighboring protein-coding genes in cis or in trans. [28] [29] [30] Moreover, microarray analysis revealed that lncRNA RP5-833A20.1 expression was upregulated, whereas NFIA expression was downregulated in THP-1 macrophage-derived foam cells (Tables I and II in the  online-only Data Supplement) . Thus, we hypothesized that RP5-833A20.1 might negatively regulate NFIA expression in cis. Next, we verified the effects of oxidized low-density lipoprotein (Ox-LDL) and acetylated low-density lipoprotein (Ac-LDL) on expression levels of RP5-833A20.1 and NFIA in THP-1 macrophages by quantitative reverse transcription polymerase chain reaction and Western blot analysis. As shown in Figure 1H and 1I, RP5-833A20.1 expression levels were obviously induced by Ox-LDL and Ac-LDL in a dose-and timedependent manner. On the contrary, mRNA and protein levels of NFIA were significantly inhibited by Ox-LDL and Ac-LDL treatment in a dose-and time-dependent manner.
RP5-833A20.1 Suppressed NFIA Expression by Promoting miR-382-5p Expression
As indicated above, quantitative reverse transcription polymerase chain reaction and Western blot analysis showed that RP5-833A20.1 expression was upregulated, whereas NFIA expression was downregulated by Ox-LDL and Ac-LDL. Bioinformatic analysis (http://genome.ucsc.edu) revealed that lncRNA RP5-833A20.1 was located in intron 2 of the NFIA gene and had an opposite transcription direction to that of NFIA ( Figure 1G ). In addition, previous studies indicated that some antisense lncRNAs with opposite transcription directions might inhibit expression of the host gene. 31, 32 Therefore, we propose the hypothesis that RP5-833A20.1 may negatively regulate NFIA expression and then explored the effects of RP5-833A20.1 on NFIA expression and related mechanisms. As shown in Figure 2A to 2C, both mRNA and protein levels were markedly inhibited by lentivirus-mediated overexpression of lncRNA RP5-833A20.1, whereas enhanced by lentivirus-mediated knockdown of lncRNA RP5-833A20.1. Subsequently, localization of RP5-833A20.1 and NFIA in THP-1 macrophages was detected by immunofluorescence confocal microscopy ( Figure 2D ). The results showed that RP5-833A20.1 and NFIA had similar distribution patterns inside and around the nuclear region. In addition, when the THP-1 macrophages were incubated with empty lentivirus vectors, no intracellular change in NFIA signaling was revealed. When the cells were incubated with lentivirus-mediated knockdown of lncRNA RP5-833A20.1, the NFIA signals were increased with enhancement of fluorescent density for lentivirus-siRNA-RP5-833A20.1. When cells were incubated with lentiviruses to overexpress lncRNA RP5-833A20.1, the NFIA signals were decreased with enhancement of fluorescent density for lentivirus-RP5-833A20.1. These findings further demonstrated that NFIA expression could be inhibited by lncRNA RP5-833A20.1.
Recent studies have suggested that lncRNAs could interact with other classes of noncoding RNAs, including microR-NAs, and modulate their regulatory roles through interactions. [33] [34] [35] Thus, we then investigate whether RP5-833A20.1 decreased NFIA expression through a microRNA signaling pathway. The target prediction algorithms miRBase, PicTar, TargetScan, and RNAhybrid predicted that hsa-miR-138-2-3p, hsa-miR-191-3p, hsa-miR-29b-1-5p, hsa-miR-29b-2-5p, hsa-miR-29b-3p, hsa-miR-29c-5p, hsa-miR-29c-3p, hsa-miR-367-5p, hsa-miR-367-3p, hsa-miR-382-5p, hsa-miR-382-3p, hsa-miR-424-5p, hsa-miR-424-3p, hsa-miR-539-5p, and hsa-miR-539-3p were putative regulators of NFIA. To explore whether NFIA downregulation was associated with microRNA expression, we next investigated the effects of mimics of the 15 putative microRNAs on NFIA expression in THP-1 macrophages. As shown in Figure 2E , NFIA mRNA levels were significantly downregulated by mimics of hsa-miR-29b-2-5p, hsa-miR-29b-3p, hsa-miR-29c-3p, hsa-miR-367-3p, hsa-miR-382-5p, hsa-miR-382-3p, hsa-miR-424-5p, Figure 1 . Continued Microarray expression profiling of mRNAs and long non-protein-coding RNAs (lncRNAs) was performed using human acute monocytic leukemia (THP-1) macrophages and THP-1 macrophage-derived foam cells. A, A flow chart of the strategy for systematic discovery of candidate lncRNAs and their target genes. B, A strategy to enrich biologically relevant lncRNA and mRNA. Different expression levels of mRNA and lncRNA indicating a fold change >3 and a P value <0.01. C, Pearson correlation was performed between lncRNA and mRNA expression values, and the correlation of 63 differentially expressed mRNA with all 24 748 lncRNAs was shown. D, Pearson correlation was performed between lncRNA and mRNA expression values, and the correlations between 157 selected lncRNAs and 98 selected mRNAs was shown. E, Hierarchical clustering based on the 157 selected lncRNAs and 98 selected mRNAs. F, Zoom in version of the built network. Genes marked with a red dot indicate upregulation, whereas those marked with a blue dot indicate downregulation. No dot suggests nonsignificant regulation. G, LncRNA RP5-833A20.1 is located in intron 2 of the nuclear factor IA (NFIA) gene and has an opposite transcription direction to NFIA. H, Effects of acetylated low-density lipoprotein (Ac-LDL)/oxidized low-density lipoprotein (Ox-LDL) on expression of RP5-833A20.1 and NFIA in THP-1 macrophages. a and c, THP-1 macrophages were treated with Ac-LDL/Ox-LDL at 0, 25, 50, and 100 μg/mL for 48 hours, respectively. b and d, THP-1 macrophages were treated with 50 μg/mL of Ac-LDL/Ox-LDL for 0, 12, 24, and 48 hours, respectively. The expression levels of RP5-833A20.1 and NFIA were measured by quantitative reverse transcription polymerase chain reaction (PCR). I, THP-1 macrophages were treated with Ac-LDL/Ox-LDL at 0, 25, 50, and 100 μg/mL for 48 hours or treated with 50 μg/mL of Ac-LDL/Ox-LDL for 0, 12, 24, and 48 hours, respectively. NFIA expression levels were measured by Western blot analysis. All results are expressed as mean±SD of 3 independent experiments, each performed in triplicate. *P<0.05 vs control. PMA indicates phorbol-12-myristate-13-acetate; and UCSC, University of California Santa Cruz.
hsa-miR-424-3p, hsa-miR-539-5p, and hsa-miR-539-3p. In addition, NFIA protein expression was markedly downregulated by hsa-miR-382-5p mimics, whereas upregulated by an hsa-miR-382-5p inhibitor ( Figure 2F ). Next, we explored whether NFIA could be directly regulated by hsa-miR-382-5p using a luciferase assay. After cotransfection with hsa-miR-382-5p and pMIR-apoM-wild-type vectors, luciferase activity was significantly decreased. This effect was significantly abolished by substituting this vector with its mutant version ( Figure 2G ).
We subsequently investigated whether hsa-miR-382-5p was involved in regulation of NFIA expression by RP5-833A20.1. As shown in Figure 2H , hsa-miR-382-5p levels were significantly induced by lentivirus-mediated overexpression of lncRNA RP5-833A20.1, whereas inhibited by lentivirus-mediated knockdown of lncRNA RP5-833A20.1. To investigate how lncRNA RP5-833A20.1 is able to regulate the expression of miR-382-5p, the levels of pri-miR-382-5p and pre-miR-382-5p and mature hsa-miR-382-5p were measured by real-time quantitative polymerase chain reaction analysis. Interestingly, increase in mature hsa-miR-382-5p levels was accompanied by upregulation of pre-miR-382-5p, but not pri-miR-382-5p, suggesting the involvement of posttranscriptional mechanisms ( Figure 2I ). Furthermore, we found that hsa-miR-382-5p levels were obviously induced by Ox-LDL and Ac-LDL in a dose-and time-dependent manner ( Figure 2J ). In addition, suppression of NFIA protein expression induced by lentivirus-mediated overexpression of lncRNA RP5-833A20.1 was almost totally compensated by hsa-miR-382-5p inhibition ( Figure 2K ). Moreover, treatment with hsa-miR-382-5p mimics led to a more significant reduction in NFIA protein expression than lentivirus-mediated lncRNA RP5-833A20.1 overexpression ( Figure 2K ). Furthermore, NFIA protein expression in cells treated by the combination of lentivirus-siRNA-RP5-833A20.1 and miR-382-5p inhibitor was significantly increased as compared with these treated by lentivirus-siRNA-RP5-833A20.1 alone ( Figure 2K ). These results revealed that RP5-833A20.1 decreased NFIA expression through the hsa-miR-382-5p pathway.
Interestingly, pathway analysis of the 98 selected genes indicated above using Ingenuity Pathway Analysis (www. ingenuity.com) revealed that the NFIA gene may have a function of self-regulation ( Figure ID in the online-only Data Supplement). Therefore, we hypothesized that NFIA could self-regulate its expression through a RP5-833A20.1mediated pathway. As shown in Figure 2L , lentivirus-mediated NFIA overexpression significantly increased lncRNA RP5-833A20.1 expression levels in THP-1 macrophages. On the contrary, lncRNA RP5-833A20.1 expression levels were markedly suppressed by lentivirus-mediated NFIA knockdown in THP-1 macrophages ( Figure 2M ). Because NFIA could modulate DNA replication and transcription through binding to duplex DNA containing the 5′-TTGGCN 5 GCCAA-3′ consensus sequence with high affinity as a transcription factor, 11 we analyzed the upstream region of RP5-833A20.1 and identified a putative NFIA response element at ≈1800 upstream of RP5-833A20.1 ( Figure 2N ). Luciferase assays indicated that NFIA induced the promoter activity of RP5-833A20.1 by a 2.3-fold ( Figure 2N ). Moreover, we found that this effect was significantly abolished by substituting this vector with its mutant version ( Figure 2N ). In addition, we performed NFIA chromatin immunoprecipitation in THP-1 macrophages. On Ox-LDL or Ac-LDL signaling, NFIA showed a significant increase in binding to the promoters of RP5-833A20.1 ( Figure 2N ). These results indicate that RP5-833A20.1 is a directly transcriptional target of NFIA. In addition to THP-1 Figure 2 . Continued RP5-833A20.1 suppressed nuclear factor IA (NFIA) expression by promoting miR-382-5p expression. A to C, Human acute monocytic leukemia (THP-1) macrophages were treated with lentivirus-Mock (LV-Mock), LV-small interfering RNA (siRNA)-RP5-833A20.1, or LV-RP5-833A20.1, and then RNA and protein levels were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot analysis, respectively. D, THP-1 macrophages were treated with LV-Mock, LV-siRNA-RP5-833A20.1, or LV-RP5-833A20.1, and then the localization of RP5-833A20.1 and NFIA was determined by immunofluorescence confocal microscopy. The blue fluorescence and red fluorescence indicate the locations of nuclear region and NFIA, respectively. The green fluorescence represents the locations of LV-Mock, LV-siRNA-RP5-833A20.1, and LV-RP5-833A20.1as indicated. (a) 4',6-diamidino-2-phenylindole (blue fluorescence); (b) LV-Mock, LV-siRNA-RP5-833A20.1, or LV-RP5-833A20.1, as indicated (green fluorescence); (c) a merged image of (a) and (b); (d) NFIA (red fluorescence); (e) a merged image of (a) and (d); (f) a merged image of (b) and (d); (g) a merged image of (a), (b), and (d). E and F, THP-1 macrophages were treated with 50 nmol/L miRNA mimics or inhibitor as indicated for 48 hours. The NFIA mRNA and protein levels were measured by qRT-PCR and Western blot analysis, respectively. G, Hsa-miR-382-5p directly targets the 3′ untranslated region (UTR) of NFIA. (a) Sequence alignment of the human hsa-miR-382-5p mature sequence with the binding sites of the human NFIA 3′UTR. (b) Changes in luciferase activity by the hsa-miR-382-5p mimic in the NFIA 3′UTR (n=3; *P<0.01 vs 293T cells transfected with negative control miRNAs). H, THP-1 macrophages were treated with LV-Mock, LV-siRNA-RP5-833A20.1, or LV-RP5-833A20.1, and then hsa-miR-382-5p levels were measured by qRT-PCR. I, THP-1 macrophages were treated with LV-Mock and LV-RP5-833A20.1, and then levels of pri-miR-382-5p and pre-miR-382-5p and mature hsa-miR-382-5p were measured by qRT-PCR. J, THP-1 macrophages were treated with acetylated low-density lipoprotein (Ac-LDL)/oxidized low-density lipoprotein (Ox-LDL) at 0, 25, 50, and 100 μg/mL for 48 hours or treated with 50 μg/mL of Ac-LDL/Ox-LDL for 0, 12, 24, and 48 hours, and then hsa-miR-382-5p levels were measured by qRT-PCR. K, THP-1 macrophages were treated as indicated and then NFIA protein levels were measured by Western blot analysis. Data are presented as mean±SD of 3 independent experiments. *P<0.05 vs control group; #P<0.05 vs hsa-miR-382-5p mimic/inhibitor group; &P<0.05 vs LV-RP5-833A20.1/LV-siRNA -RP5-833A20.1 group. L and M, THP-1 macrophages were treated with LV-Mock, LV-NFIA, negative control, or si-NFIA as indicated and then RP5-833A20.1 levels were measured by qRT-PCR. N, (a) Schematic description of RP5-833A20.1 promoter with a potential NFIA response element (NFIA RE). Also shown are sequences for mutant NFIA RE and NFIA RE consensus. Relative position of primers used for chromatin immunoprecipitation (ChIP) assay (c) was indicated by arrows. (b) Induction of RP5-833A20.1 promoter activity by NFIA through binding wild-type NFIA RE, but not mutant NFIA RE (n=3; *P<0.01 vs THP-1 macrophages transfected with control vectors). (c) THP-1 macrophages were treated with or without 50 μg/mL Ox-LDL/Ac-LDL as indicated for 48 hours. ChIP with NFIA antibodies was performed and NFIA percent enrichment relative to input is shown (n=3; *P<0.01 vs control group). O, HepG2 cells, Caco-2 cells, Eahy926 cells, and primary macrophages were treated with LV-Mock, LV-RP5-833A20.1, negative control, or miR-382-5p mimic as indicated and then NFIA protein levels were measured by Western blot analysis. P, HepG2 cells, Caco-2 cells, Eahy926 cells, and primary macrophages were treated with LV-Mock and LV-NFIA, and then RP5-833A20.1 levels were measured by qRT-PCR. All data are presented as mean±SD of 3 independent experiments. *P<0.05 vs control group unless otherwise noted. macrophages, NFIA protein expression was inhibited by lentivirus-mediated overexpression of RP5-833A20.1 and hsa-miR-382-5p, and lncRNA RP5-833A20.1 expression was induced by lentivirus-mediated NFIA overexpression in various cell lines, including HepG2, Caco-2, and Eahy926 cells, as well as primary macrophages ( Figure 2O and 2P). Together, these results suggested that NFIA may have a function of selfregulation through interactions with lncRNA RP5-833A20.1 and hsa-miR-382-5p.
RP5-833A20.1/hsa-miR-382-5p/NFIA Regulates Cholesterol Homeostasis and Inflammatory Cytokines
First, we investigated the role of RP5-833A20.1/hsa-miR-382-5p/NFIA on lipid loading in THP-1 macrophages via flow cytometry. As shown in Figure 3A , indocarbocyanine dye (DiI)-labeled Ox-LDL uptake was increased by lentivirus-mediated overexpression of RP5-833A20.1 and hsa-miR-382-5p mimics, whereas reduced by lentivirus-mediated NFIA overexpression. Next, we examined the effect of RP5-833A20.1/hsa-miR-382-5p/NFIA on cholesterol content and efflux in THP-1 macrophage-derived foam cells. As shown, cellular cholesterol content ( Figure 3B ) was increased, whereas cholesterol efflux ( Figure 3C ) was decreased in cells treated with lentivirus-mediated overexpression of RP5-833A20.1 and hsa-miR-382-5p mimics. On the contrary, cellular cholesterol content ( Figure 3B ) was decreased, whereas cholesterol efflux ( Figure 3C ) was increased by lentivirusmediated NFIA overexpression. In addition, we investigated the effect of RP5-833A20.1/hsa-miR-382-5p/NFIA on lipid accumulation in THP-1 macrophage-derived foam cells by Oil Red O staining. As shown in Figure II in the online-only Data Supplement, lipid accumulation was increased by lentivirus-mediated overexpression of RP5-833A20.1 and hsa-miR-382-5p mimics, whereas reduced by lentivirus-mediated NFIA overexpression in THP-1 macrophage-derived foam cells. Furthermore, we found that levels of lipopolysaccharide-stimulated proinflammatory cytokines, including tumor necrosis factor-α, interleukin (IL)-1β, and IL-6, were upregulated by lentivirus-mediated overexpression of RP5-833A20.1 and hsa-miR-382-5p mimics, whereas downregulated by lentivirus-mediated NFIA overexpression in THP-1 macrophages ( Figure 3D ).
Subsequently, we explored the mechanisms underlying the altered cellular lipid profile and inflammatory cytokines by RP5-833A20.1/hsa-miR-382-5p/NFIA in THP-1 macrophages. For this purpose, we assessed protein expression of ATP-binding cassette (ABC), subfamily A, member 1 (ABCA1); ABC subfamily G, member 1 (ABCG1); scavenger receptor class B, member 1; Niemann-Pick disease, type C1 (NPC1); steroid receptor RNA activator 1 (SRA1); cluster of differentiation 36 (CD36); liver X receptor-α; peroxisome proliferator-activated receptor-γ; and nuclear factor κ-light chain enhancer of activated B cells (NF-κB) in THP-1 macrophages. As shown in Figure 3E and 3F, protein levels of ABCA1 and ABCG1 were downregulated by lentivirusmediated overexpression of RP5-833A20.1 and hsa-miR-382-5p mimics, whereas upregulated by lentivirus-mediated NFIA overexpression. Treatment with siRNA targeting NFIA downregulated ABCA1 and ABCG1 expression induced by overexpression of RP5-833A20.1 or hsa-miR-382-5p mimics even more obviously. In addition, SRA1, CD36, and NF-κB were upregulated by lentivirus-mediated overexpression of RP5-833A20.1 and hsa-miR-382-5p mimics, whereas downregulated by lentivirus-mediated NFIA overexpression. The upregulation of SRA1, CD36, and NF-κB expression induced by overexpression of RP5-833A20.1 or hsa-miR-382-5p mimics was completely abolished by siRNA-mediated silencing of NFIA. These results suggest that downregulation of ABCA1 and ABCG1 expression and upregulation of SRA1, CD36, and NF-κB expression induced by RP5-833A20.1 or hsa-miR-382-5p are mediated by NFIA in THP-1 macrophages.
NFIA Treatment Increases Reverse Cholesterol Transport and Decreases Circulating Cytokine Levels In Vivo
To investigate the effects of NFIA on reverse cholesterol transport (RCT) and atherosclerosis progression in vivo, tissue-specific NFIA mRNA expression in various tissues of C57BL/6 mice was analyzed. As shown in Figure 4A , NFIA was widely expressed in mouse tissues and highest in the heart, liver, lung, kidney, brain, and aorta and to a lesser extent in the colon, stomach, and small intestine. In addition, NFIA RNA expression was increased in the liver, spleen, brain, and aorta when mice were fed a high-fat diet (HFD). Furthermore, sections of liver and aorta stained immunohistochemically with antibody against NFIA revealed that NFIA protein expression was significantly upregulated in apolipoprotein E-deficient (apoE −/− ) mice when fed with a HFD. The expression of NFIA and CD68-positive cells (predominately macrophages Figure 3 . Continued Effect of RP5-833A20.1/hsa-miR-382-5p/nuclear factor IA (NFIA) on lipid loading, lipid content, cholesterol efflux, and lipopolysaccharide (LPS)-induced inflammatory cytokines. A to E, Human acute monocytic leukemia macrophages were treated with lentivirus (LV)-Mock (control) and LV-RP5-833A20.1, negative control, miR-382-5p mimic, LV-Mock (control), and LV-NFIA as indicated, respectively. A, Cells were incubated with 5 μg/mL of DiI-labeled oxidized low-density lipoprotein (Ox-LDL) for 24 hours and uptake of DiI-labeled Ox-LDL was analyzed by flow cytometry. B, High-performance liquid chromatography was performed to determine the cellular total cholesterol (TC), free cholesterol (FC), and cholesterol ester (CE) content. C, Cellular cholesterol efflux was analyzed using liquid scintillation counting assays. D, Cells were incubated with 10 ng/mL of LPS for 24 hours and the secreted inflammatory cytokines were quantified using an ELISA. E, The protein levels were measured by Western blot analysis. The results are expressed as mean±SD from 3 independent experiments, each performed in triplicate. *P<0.05 vs control group. F, THP-1 macrophages were treated with LV-Mock/ negative control (control), LV-RP5-833A20.1/miR-382-5p mimic, NFIA small interfering RNA (siRNA), and LV-RP5-833A20.1+NFIA siRNA/ miR-382-5p mimic+NFIA siRNA as indicated. The protein levels were measured by Western blot analysis. The results are expressed as mean±SD from 3 independent experiments, each performed in triplicate. *P<0.05 vs control group. #P<0.05 vs LV-RP5-833A20.1/miR-382-5p mimic group. ABCA1 indicates ATP-binding cassette, subfamily A, member 1; ABCG1, ATP-binding cassette subfamily G, member 1; apoA1, apolipoprotein A1; CD36, cluster of differentiation 36; HDL, high-density lipoprotein; IL, interleukin; LXRα, liver X receptor-α; NF-κB, nuclear factor κ-light chain enhancer of activated B cells; NPC1, Niemann-Pick disease, type C1; PPARγ, peroxisome proliferatoractivated receptor-γ; SRA1, steroid receptor RNA activator 1; SRB1, scavenger receptor B1; and TNFα, tumor necrosis factor-α. and macrophage-foam cells) in the aorta was next examined using double immunohistochemical staining ( Figure III in the online-only Data Supplement). We found that HFD treatment resulted in a significant increase in NFIA expression in the plaque area although the number of CD68-positive cells in the observed plaques of the HFD-treated group was greater than that in the control group. In addition, we found that HFD treatment resulted in a significant increase of NFIA expression in CD68-negative cells, whereas a significant decrease of that in CD68-positive cells in the observed plaques. This result may explain, at least in part, why Ox-LDL and Ac-LDL downregulate NFIA expression in macrophages but its expression is upregulated in the aorta after HFD feeding.
Next, we investigated the effects of NFIA on liver morphology and lipid content in apoE −/− mice by hematoxylin and eosin staining and Oil Red O staining, respectively ( Figure 4B ). The protein expression of NFIA in mouse liver was investigated by immunohistochemistry analyses. As shown in Figure IV in the online-only Data Supplement, the NFIA-treated (lentivirus-NFIA) groups had significantly higher expression of NFIA than their control groups (lentivirus-Mock). Representative images of randomly selected hematoxylin and eosin-stained liver sections in the control and the lentivirus-NFIA groups are shown in Figure 4B . Based on the number of vacuoles and nuclear size, lentivirus-NFIA-treated mice had significantly reduced levels of hepatic steatosis compared with lentivirus-Mock-treated mice (P<0.05). Furthermore, we found that lentivirus-NFIA-treated mice had significantly reduced hepatic lipid content compared with lentivirus-Mock-treated mice (P<0.05). We also examined the terminal plasma lipid levels in the experimental mice. As shown in Table 1 , lentivirus-NFIA-treated mice had a 33.6% increase in plasma high-density lipoprotein cholesterol (HDL-C) levels, a 36.1% decrease in plasma low-density lipoprotein cholesterol (LDL-C) levels, and a 46.7% decrease in plasma very-low-density lipoprotein cholesterol (VLDL-C) levels compared with lentivirus-Mock-treated mice. In these experiments, there was no apparent hepatotoxicity (as measured by plasma aspartate aminotransferase/alanine aminotransferase, data not shown).
To investigate whether higher HDL levels in response to lentivirus-NFIA treatment could upregulate cholesterol transport from peripheral cells to the liver for further excretion into bile and feces, we performed an in vivo RCT assay to trace 3H-cholesterol from cholesterol-loaded macrophages ex vivo ( Figure 4C ). Lentivirus-NFIA-treated mice subcutaneously injected with cholesterol-loaded/3H cholesterol-labeled bone marrow-derived macrophages showed a 25.5% increase in plasma 3H-cholesterol content for 48 hours compared with that of lentivirus-Mock-treated mice. Furthermore, lentivirus-NFIA-treated mice showed a 29.3% increase in the delivery of a 3H tracer to the liver and a 47.9% increase in 3H sterols excreted into the feces. These results suggested that enhanced NFIA expression could not only increase circulating HDL-C levels and decrease circulating LDL-C and VLDL-C levels but also enhance the RCT pathway in vivo.
To determine whether NFIA-mediated changes in cellular proinflammatory gene expression influenced the corresponding changes in plasma inflammatory cytokine content, we conducted a series of ELISA (Table 2 ). Consistent with the inflammatory gene expression data in THP-1 macrophages, lentivirus-NFIA treatment resulted in downregulation of IL-1β, IL-6, tumor necrosis factor-α, and C-reactive protein plasma concentrations in apoE −/− mice by 32.7%, 55.1%, 43.2%, and 29.6%, respectively.
Subsequently, protein expression of a series of genes involved in liver lipid metabolism and intestinal lipid absorption in apoE −/− mice tissues was investigated by Western blot analyses. As shown in Figure 4D , the lentivirus-NFIA-treated liver tissues had significantly higher expression levels of ABCA1, ABCG1, ABCG5, apoA1, and low-density lipoprotein receptor and lower expression of NF-κB than the lentivirus-Mock-treated liver tissues, whereas the lentivirus-NFIA-treated group showed no changes in expression levels of NPC1; scavenger receptor class B, member 1; hydroxymethylglutaryl-coA synthase; hydroxymethylglutaryl-coA synthase receptor; liver X receptor-α; or peroxisome proliferator-activated receptor-γ as compared with lentivirus-Mock-treated liver tissues. Subsequently, protein expression levels in the small intestine tissues of apoE −/− mice were analyzed by Western blot analyses ( Figure 4E ). The lentivirus-NFIA-treated group showed markedly enhanced protein levels of ABCA1 and ABCG5 and reduced Niemann-Pick C1-like 1 (NPC1L1) protein levels compared with the lentivirus-Mock-treated group. Moreover, lentivirus-NFIA-treated Caco-2 cells had markedly increased protein levels of ABCA1 and ABCG5, whereas decreased NPC1L1 protein levels compared with lentivirus-Mock-treated cells. 
NFIA Treatment Suppresses Atherosclerosis Plaque Formation
To further understand the effects of NFIA on atherogenesis in apoE −/− mice, atherosclerotic lesions were evaluated by aortic valve section and en face analyses ( Figure 5A ). Mice receiving lentivirus-mediated NFIA overexpression showed a decrease in average lesion area compared with controls by both en face and aortic valve section analyses. Quantification of Oil Red O-stained aortic valve sections revealed that lentivirus-NFIA treatment resulted in a significant decrease in total lesion area (53.3%) and in Oil Red O-positive lesion area (44.4%) in apoE −/− mice when compared with controls. To further investigate the positive effects of NFIA on atherosclerosis, Oil Red O-stained lesions in en face preparations of aortas were quantified. The results showed the lentivirus-NFIA treatment of apoE −/− mice led to a significant increase (42.1%) in lesion area compared with controls. Subsequently, the composition of the observed plaques was determined by immunohistochemical staining techniques. As shown in Figure 5B , the number of CD68 + cells (predominately macrophages and macrophage-foam cells) in the observed plaques of the lentivirus-NFIA-treated group was less than that in the control group. Lentivirus-NFIA treatment resulted in a significant decrease (34.3%) in integral optical density of CD68 + cells in the plaque area. In addition, no difference in lesional apoptosis, as measured by terminal deoxynucleotidyl transferase 2′-deoxyuridine 5′-triphosphate nick end labelingpositive cells in plaques, was noted between the control and treatment groups (data not shown). Furthermore, ABCA1 expression was also determined by immunohistochemical staining techniques. As shown in Figure 5B , lentivirus-NFIA treatment resulted in a significant increase (92.1%) in integral optical density of ABCA1 expression in the plaque area.
To explore the mechanisms whereby NFIA treatment inhibited plaque progression and stabilization, protein expression changes of the inflammatory factors, adhesion molecules, chemotactic factors, and molecules involved in cellular cholesterol efflux were investigated in the aorta of apoE −/− mice ( Figure 5C ). In lentivirus-NFIA-treated apoE −/− mice, protein expression of ABCA1 and ABCG1 was markedly increased, but protein expression of monocyte chemotactic protein-1 and NF-κB was suppressed at 12 weeks. In addition, lentivirus-NFIA treatment did not alter protein expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, liver X receptor-α, and peroxisome proliferator-activated receptor-γ in apoE −/− mice.
Discussion
Atherosclerosis and its clinical manifestations are the leading causes of morbidity and mortality in Western countries. 1 Formation of macrophage-foam cells in the intima is a major hallmark of early stage atherosclerotic lesions. Uncontrolled Ox-LDL uptake, excessive cholesterol esterification, and impaired cholesterol release can provoke accumulation of cholesterol ester stored as cytoplasmic lipid droplets and accordingly trigger foam cell formation. 9, 36 Analysis of lncRNAs in CVD is still in its infancy and the full impact of this field on cardiovascular biology is yet to be realized. 22 In the present study, we demonstrated that lncRNA RP5-833A20.1 may first downregulate NFIA expression by induction of hsa-miR-382-5p expression and then promote formation of THP-1 macrophage-derived foam cells. In addition, we showed that NFIA promoted RCT and decreased circulating cytokine levels and, thereby, significantly suppressed atherosclerotic plaque formation in apoE −/− mice fed a HFD/high-cholesterol diet.
LncRNAs are a recently discovered class of non-proteincoding RNAs, which have increasingly been shown to be involved in the regulation of a wide variety of biological processes. RNA-seq studies have provided a genome-wide view of where lncRNAs are transcribed relative to coding regions. The lncRNAs can be distinguished as several classes including antisense transcripts of protein-coding genes, bidirectional promoter transcripts, transcripts associated with enhancers or repetitive regions, and other transcripts originating in intergenic regions. 37, 38 Bioinformatic analysis revealed that the lncRNA RP5-833A20.1 was located in intron 2 of the NFIA gene and has an opposite transcription direction to NFIA. These findings indicated that RP5-833A20.1 may inhibit NFIA expression. Our results showed that NFIA expression was significantly inhibited at the transcriptional and post-transcriptional levels. MicroRNAs are one of the most recently discovered and well-characterized classes of ncRNAs and are small regulatory RNA molecules processed from larger precursors through a highly coordinated pathway. 39, 40 Presently, microRNAs are known to mediate post-transcriptional control of gene expression by binding to the 3′-untranslated regions of protein-coding genes. 41, 42 Recent observations have suggested that lncRNAs may interact with other classes of noncoding RNAs, including microRNAs, and modulate their regulatory roles through interactions 34 to 36. The target prediction algorithms miRBase, PicTar, TargetScan, and RNAhybrid predicted that hsa-miR-382-5p was a putative NFIA regulator. In addition, NFIA expression was markedly downregulated by hsa-miR-382-5p mimics, whereas upregulated by hsa-miR-382-5p inhibitors. A luciferase assay further demonstrated that hsa-miR-382-5p directly targeted NFIA. However, hsa-miR-382-5p expression was significantly upregulated by RP5-833A20.1 and suppression of NFIA expression by lncRNA RP5-833A20.1 was almost compensated by hsa-miR-382-5p inhibition. These results suggested that RP5-833A20.1 decreased NFIA expression through the hsa-miR-382-5p pathway. Moreover, we found that protein levels of ABCA1 and ABCG1 were downregulated by overexpression of RP5-833A20.1 and hsa-miR-382-5p mimics, whereas upregulated by overexpression of NFIA. Treatment with siRNA targeting of NFIA made the downregulation of ABCA1 and ABCG1 expression induced by overexpression of RP5-833A20.1 or hsa-miR-382-5p mimics even more obvious. In addition, SRA1, CD36, and NF-κB were upregulated by overexpression of RP5-833A20.1 and hsa-miR-382-5p mimics, whereas downregulated by NFIA overexpression. The upregulation of SRA1, CD36, and NF-κB expression induced by overexpression of RP5-833A20.1 or hsa-miR-382-5p mimics was completely abolished by siRNA-mediated silencing of NFIA. These results suggest that the downregulation of ABCA1 and ABCG1 expression and upregulation of SRA1, CD36, and NF-κB expression induced by RP5-833A20.1 or hsa-miR-382-5p are mediated by NFIA in THP-1 macrophages. Furthermore, we found that protein expression of ABCA1 and ABCG1 was increased, but protein expression of monocyte chemotactic protein-1 and NF-κB was suppressed in the aorta of lentivirus-NFIA-treated apoE −/− mice. A previous study revealed that NFIA can modulate DNA replication and transcription through binding to duplex DNA containing the TTGGC motif or 5′-TTGGCN 5 GCCAA-3′ consensus sequence. 12 Remarkably, little is known about the direct downstream target genes of the nuclear transcription factor NFIA. Thus, whether these genes can be directly regulated by NFIA or whether another mechanism is involved needs to be further explored. Recent observations have found that lncRNA expression could be regulated by transcription factors. For example, lncRNA highly up-regulated in liver cancer expression was found to be regulated by the transcription factor, cAMP-responsive element binding protein, in Hep3B cells. 43 LncRNA antisense noncoding RNA in the INK4 locus (CDKN2B-antisense) is induced by the E2F1 transcription after DNA damage. 44 LncRNA Kcna2 (potassium voltage-gated channel, shaker-related subfamily, member 2) expression is increased in injured dorsal root ganglia through activation of myeloid zinc finger protein 1, a transcription factor that binds to the Kcna2 gene promoter. 45 Here, we showed that lncRNA RP5-833A20.1 expression could be significantly induced by transcription factor NFIA. Taken together, our results indicated that NFIA expression may be self-regulated through the induction of hsa-miR-382-5p expression in a RP5-833A20.1-dependent manner. However, the detailed mechanisms of this process must be further investigated.
RCT is a pathway in which accumulated cholesterol is transported from the vessel wall to the liver for excretion, thereby preventing the development of atherosclerosis. In atherosclerosis, cellular cholesterol accumulates in lipidengorged macrophage-foam cells and drives lipid deposition in atherosclerotic plaques. The control of macrophage cholesterol homeostasis is of critical importance in atherosclerosis pathogenesis, as dysregulation of the balance of cholesterol influx, intracellular transport, and efflux will lead to excessive cholesterol accumulation in macrophages and their transformation into foam cells. 46, 47 We found that NFIA significantly stimulated expression of ABCA1 and ABCG1, which are key genes involved in the mediation of cholesterol transport across cellular membranes, 9, 48 thereby greatly inhibiting expression of SRA1 and CD36, which is a crucial protein involved in binding and uptake of Ox-LDL in macrophages, 9, 49 which, in turn, markedly upregulates expression of ABCG5, a crucial protein involved in the prevention of intestinal absorption of excess dietary cholesterol from the gut and enhancement of cholesterol efflux from hepatocytes into bile, 9, 50 thereby significantly suppressing NPC1L1 expression, which is responsible for promoting intestinal cholesterol absorption 9,51 and significantly upregulating expression of apoA1, a crucial protein involved in promoting cellular cholesterol efflux and forming mature HDL-C. 9, 52 Consistent with these observations, enhanced NFIA expression not only increased circulating HDL-C levels and decreased circulating LDL-C and VLDL-C levels but also enhanced the RCT pathway in apoE −/− mice fed a HFD/high-cholesterol diet. These results provide a strong evidence to support the notion that NFIA exerts its antiatherogenic effects by promoting the rate of RCT.
It is known that atherosclerosis is a lipid disorder and a chronic inflammatory disease. Inflammatory processes take part in all stages of the atherosclerotic process, from lesion initiation to plaque rupture. 53, 54 Macrophages, whether engorged with lipids or not, play a key role in inflammation mediation and modulation, and much atherosclerosis research has targeted the role of macrophages in the inflammatory pathways that underlie atherogenesis. 3, [55] [56] [57] In the present study, we showed that NFIA significantly decreased the concentration of CD68 + cells in plaque areas of apoE −/− mice. In addition, we found that NFIA significantly downregulated NF-κB expression in vivo and in vitro. Consistent with these observations, enhancement of NFIA expression not only decreased levels of lipopolysaccharide-stimulated proinflammatory cytokines, including tumor necrosis factor-α, IL-1β, and IL-6, in THP-1 macrophages, but also decreased circulating cytokine levels in apoE −/− mice fed a HFD/high-cholesterol diet. Our results suggested that NFIAinduced suppression of inflammatory cytokine expression levels could block or retard the development of atherosclerotic lesions and thus have a positive influence on disease outcomes.
Atherosclerosis is a multifactorial highly complex disease with numerous pathogeneses that work synergistically to promote lesion development. The mouse is the most useful, economical, and validated model to mimic humans metabolically and pathophysiologically to study atherosclerosis and explore effective therapeutic approaches. 58 ApoE is synthesized by the liver and macrophages and has several important antiatherogenic functions. 59 Lesions of apoE −/− mice resemble their human counterparts and develop over time from initial fatty streaks to complex lesions. 60, 61 In the present study, we found that NFIA overexpression could increase circulation of HDL-C, reduce circulation of LDL-C and VLDL-C, decrease circulation of inflammatory cytokines, enhance RCT, and promote regression of atherosclerosis in apoE −/− mice. These findings indicate that NFIA may be a promising candidate as a therapeutic agent. However, differences in anatomy, lipid metabolism, and gene expression complicate translation of experimental results obtained in mice to humans. 58, 62, 63 For example, differences in the location of atherosclerotic plaques (aorta in mice versus coronary arteries in humans), the course of disease (fulminate in mice versus indolent in humans), and the absence of endstage ischemic lesions, as well as the fact that murine atherosclerosis is not associated with occlusive coronary artery disease, myocardial infarction, cardiac dysfunction, and premature death, which are the hallmarks of human coronary heart disease, might hinder the translation of these findings from mice to humans. 58, 64 In addition, transcription factors that control gene expression in 1 species might not be crucial regulators in another. 64, 65 For example, apoAI and AII are upregulated by peroxisome proliferator-activated receptor-α agonists in humans but downregulated in mice. 65 Therefore, although NFIA should be considered as a potential target to treat atherosclerotic vascular disease, a better understanding of the applicability of laboratory findings to humans and the realization of therapeutic promise require further investigation.
In conclusion, the current study demonstrated that the RP5-833A20.1/hsa-miR-382-5p/NFIA pathway was essential to regulate cholesterol homeostasis, inflammatory responses, and foam cell formation ( Figure V in the online-only Data Supplement). In addition, NFIA overexpression in apoE −/− mice increases circulation of HDL-C, reduces circulation of LDL-C and VLDL-C, decreases circulation inflammatory cytokines, enhances RCT, and promotes the regression of atherosclerosis. Together, these results suggested that NFIA may be a promising target to treat atherosclerotic vascular disease. However, we did not investigate effects of lncRNA RP5-833A20.1 on atherosclerosis progression in vivo because the lncRNA sequence of animals had not been deciphered until now. Moreover, lentivirus was injected via tail vein to overexpress NFIA in vivo study. Thus, the tissue-specific RP5-833A20.1 KO mice and tissue-specific NFIA KO mice should be produced to confirm our results. In addition, although current study demonstrated that the RP5-833A20.1/ hsa-miR-382-5p/NFIA is a key pathway for regulating cholesterol homeostasis, inflammatory responses, and foam cell formation, whether other microRNAs can be regulated by RP5-833A20.1 and whether atherosclerosis can be affected by miR-382-5p through other targets remain unclear and need to be further explored.
